4D Announces Publication of Data Showing Potential of Single Bacterial Strains From the Human Gut Microbiota to Serve as Novel HDAC Inhibitors
LEEDS, United Kingdom, July 30, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM:DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of data showing that specific single bacterial strains from the human gut microbiota have the potential to serve as therapeutic inhibitors of the human enzyme histone deacetylase (HDAC), which is particularly relevant for disease areas involving host epigenetic aberrations.
The paper, titled "Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid" (Yuille S., et al) is published in PLOS ONE, the peer-reviewed open access scientific journal.
Overexpression of isoforms of HDAC has been implicated in a variety of diseases, including cancer, colitis, cardiovascular disease and neurodegeneration. HDAC inhibitors have a long history as therapeutic targets and the gut microbiota is known to have an influence on HDAC activity via microbial-derived metabolites. In this study, researchers used an in vitro approach to screen the 4D bacterial library to identify strains which inhibit different HDAC isoforms. One identified strain, MRx0029, was added to a model microbial consortium to assess its metabolic activity in interaction with a complex bacterial community. They found that MRx0029 successfully established in the consortium and enhanced the total and specific HDAC inhibitory function by increasing the capacity of the community to produce butyrate and valeric acid.
Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented: "This work shows that microbiome-derived live biotherapeutics can inhibit specific HDAC activity via previously unknown mechanisms. This could lead to new live biotherapeutic therapies targeting this class of enzymes for conditions including cancer, neurodegenerative disorders and inflammatory pathologies. Moreover, in developing a model microbiome consortium, we have further demonstrated the ability of single-strain live biotherapeutics to induce community-wide functional changes in the microbiome and impact disease-relevant host signaling pathways."
For further information please contact:
|4D||+ 44 (0)113 895 0130|
|Duncan Peyton, Chief Executive Officer|
|Zeus Capital Limited - Nomad and Joint Broker|
|Dan Bate / Jordan Warburton||+44 (0) 161 831 1512|
|Bryan Garnier & Co. Limited - Joint Broker||+44 (0)20 7332 2500|
Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has completed a phase I study in Irritable Bowel Syndrome and has completed dosing in a phase I study in Paediatric Crohn's Disease. It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence four additional clinical studies in 2018. For more information, refer to https://www.4dpharmaplc.com/.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 4D pharma plc via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Data Privacy and Governance Solution Now Cloud-based18.6.2019 18:34:00 CEST | Pressemelding
HIPAAT Privacy eSuite adds support for Consent as a Service, enabling consumers to have direct control over their personal information NAPLES, FL and TORONTO, ON, June 18, 2019 (GLOBE NEWSWIRE) -- HIPAAT Inc. (HIPAAT), a leading provider of consent management, privacy-based access control and auditing solutions, today announced the release of version 6.0 of its consent engine, Privacy eSuite (PeS). The new version supports consumers’ ability to have direct control over their personal information privacy preferences. Those preferences may be recorded and managed, and – most importantly – consulted prior to their information being collected, used or disclosed. V6.0 improvements include support for HL7 Fast Health Interoperability Resources (FHIR) R4 for managing privacy policies and consent directives, RESTful interfaces for consent decisions and override requests, OAuth 2.0 protection for APIs as resources, and Open ID Connect and OAuth 2.0 for authenticating users and providing user pe
Boom Supersonic Partners with Prometheus Fuels to Supply Carbon Neutral Fuel for XB-1, its Mach-2.2 Demonstrator Aircraft18.6.2019 17:00:00 CEST | Pressemelding
Prometheus Fuels extracts CO2 from the air, creating hydrocarbon fuel with zero impact on greenhouse gas levels DENVER, June 18, 2019 (GLOBE NEWSWIRE) -- Boom Supersonic, the Colorado company building history’s fastest supersonic airliner, today announced a unique partnership with Prometheus Fuels. Prometheus will supply fuel during the flight test program of XB-1, Boom’s Mach-2.2 demonstrator aircraft. Boom plans to use Prometheus fuel to power XB-1 in the world’s first supersonic flight using carbon-neutral fuel. Through a process called direct air carbon capture, Prometheus removes carbon dioxide (CO2) from the air and uses clean electricity to transform it into gasoline, diesel, and jet fuel. The electricity used in this process comes from renewable sources such as solar and wind, so there are no net carbon emissions from using the fuel. “Boom is committed to making supersonic travel environmentally sustainable—we want society to enjoy the benefits of faster flight for generations
Parallels® Remote Application Server 17 Brings Simplicity and Scalability to End User Computing for Microsoft RDS, VDI and DaaS with Time-Saving Innovations18.6.2019 15:01:00 CEST | Pressemelding
BELLEVUE, Wash., June 18, 2019 (GLOBE NEWSWIRE) -- Today Parallels released version 17 of Parallels® Remote Application Server (Parallels RAS, parallels.com/ras) which simplifies end user computing for service providers (SPs) and enterprises. Parallels RAS 17 enables faster launch of applications by using artificial intelligence (AI), provides additional security features such as integration with Google Authenticator, and debuts a web-based helpdesk console to more easily manage Microsoft Remote Desktop Services (RDS), virtual desktop infrastructure (VDI) and desktop as a service (DaaS) infrastructure. Parallels RAS 17 is an all-in-one solution that empowers end users to consume business applications faster, reliably, and with the ability to scale within a single cloud or multiple clouds. SPs and enterprises can benefit from the Parallels RAS investment in improved management and deployment components. These provide new methods to control DaaS, VDI and Microsoft RDS, such as a new REST
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease18.6.2019 14:29:00 CEST | Pressemelding
NEW YORK and CLEVELAND, June 18, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its ABO-202 program. ABO-202, the Company’s novel one-time AAV9 gene therapy for CLN1 disease, is designed to deliver a functional copy of the PPT1 gene to the central nervous system and peripheral organs using a combination of intravenous and intrathecal administrations. Abeona is preparing to initiate a Phase 1/2 clinical trial evaluating ABO-202 in patients with CLN1 disease and will provide guidance on the timing of the trial later this year. “Receiving Fast Track designation acknowledges the urgency for developing a therapy for children suffering from this rapidly-progressing and fatal disease and highlights the significant potential of ABO-202 to address this unmet need,” said João Siffert, M.D., Chief Executive Officer. ABO-202 i
Nasdaq Launches Center for Corporate Governance18.6.2019 14:00:00 CEST | Pressemelding
New Informational Hub to Advance Global Insights and Research on Corporate Governance and Sustainability Practices for Public, Private, and Nonprofit Organizations Publishes Inaugural Research Report on Board and Investor Priorities of S&P 100 Companies NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today announced the founding of the Nasdaq Center for Corporate Governance (the “Governance Center”), a global information and research hub that will integrate Nasdaq’s expertise, insights, and technology to accelerate the understanding of emerging corporate governance and sustainable business practices. The ambition of the Governance Center is to support the work of boards, senior executives, and governance professionals at public, private, and nonprofit organizations. “Our mission with the Governance Center is to create a resource for corporate leaders, investors, and stakeholders that includes the latest governance insights and actionable intelligence, thereby su
Inspirata Unveils Comprehensive Insight Solutions for the Cancer Care Continuum18.6.2019 13:00:00 CEST | Pressemelding
Leading digital pathology company now offers technology-enabled insight solutions Tampa, Florida, June 18, 2019 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology solution provider Inspirata today unveiled its new end-to-end capabilities for the cancer care continuum. Founded as a digital pathology company that pioneered the use of digital imaging for accurate cancer diagnoses, Inspirata now offers cancer registry abstraction and insight solutions to drive better cancer diagnosis, treatment, performance, and research. Inspirata’s comprehensive solutions reveal a clear picture of patients, allowing clinicians to make every moment matter in delivering cancer care. With an existing global footprint that serves over 100 institutions with automated cancer identification and reporting, and more than 30 hospitals and laboratories with digital pathology, Inspirata processes over 20 million patient reports per year, identifying all reports containing reportable cancer. Today, the comp